12:00 AM
May 06, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TT-401: Proof-of-concept trial data

A multiple ascending-dose proof-of-concept (POC) trial in 60 Type II diabetic and non-diabetic obese patients showed that the 3 highest dose levels of once-weekly TT-401 significantly reduced mean FPG from baseline to week 5 vs. placebo in Type II diabetics. Additionally, the 3 highest dose levels of TT-401 significantly reduced body weight relative to baseline. Transition said that a similar reduction...

Read the full 284 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >